Merrell Dow Pharmaceuticals

Marion Merrell Dow Canada Inc.

Gestion De La Sante Marion Merrell Dow Canada Inc.-Marion Merrell Dow Canada Health Management Inc.

John O. Johnston

Gene W. Holbert

Gene W Holbert

J O'Neal Johnston

Joseph P Burkhart

J O'neal Johnston

John O Johnston

The present invention is directed to a method for the treatment of hyperaldosteronism and related disorders which comprises administering to an appropriate patient an appropriate 18-cyanopregnane.

Method of treatment using 18-cyanoprogesterone derivatives

19-Fluoro- and cyano- substituted 21-hydroxyprogesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropriate synthetic pathways which will vary according to the nature of the specific 19-substituted progesterone or related compound desired.

19-fluoro- or cyano-21-hydroxyprogesterone derivatives useful as

19-Substituted progesterone derivatives and related compounds which are active as 19-hydroxylase inhibitors and useful as antihypertensive agents are described herein. The compounds are prepared using appropriate synthetic pathways which will vary according to the nature of the specific 19-substituted progesterone or related compound desired.

19-substituted progesterone derivatives useful as 19-hydroxylase

The present invention is directed to a group of compounds which are 3.beta.,17.beta.-hydroxy steriods, and related steroidal structures. These compounds are armatase inhibitors, and thus, regulate or inhibit the conversion of androgens to estrogens. These compounds may be utilized to treat conditions potentiated by the presence of estrogens. These compounds exhibit a slower onset of action and a longer half life relative to the 10-(2-alkynyl) steroidal aromatase inhibitors disclosed in U.S. Pat. No. 4,322,416.

3.beta.,17.beta.-hydroxy-substituted steroids and related steroidal

This application relates to a stereospecific process for preparing specific enantiomers of 4-amino-4,5-dihydro-2-furancarboxylic acid and C.sub.1-6 lower alkyl esters thereof. These compounds are .gamma.-aminobutyric acid transaminase inhibitors useful in the treatment of epilepsy.

Growing community of inventors

Loveland, OH, United States of America

Gene W Holbert